Welcome to our dedicated page for Illumina SEC filings (Ticker: ILMN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Sequencing revenue splits, consumables margins and the latest on Illumina’s GRAIL antitrust battle are scattered across hundreds of regulatory pages. If locating an Illumina annual report 10-K simplified or decoding segment data in a quarterly filing feels overwhelming, you are not alone.
Stock Titan delivers the antidote: AI-powered summaries turn raw EDGAR documents into plain language so you can move from question to answer in seconds. Whether you need an Illumina quarterly earnings report 10-Q filing, want Illumina insider trading Form 4 transactions, or prefer Illumina Form 4 insider transactions real-time alerts, every disclosure appears here moments after it hits the SEC. Our engine highlights where management discusses flow-cell demand, R&D tax credits or litigation updates and links directly to the cited page.
Use cases include:
- Benchmark consumable growth with our Illumina earnings report filing analysis.
- Track leadership moves via Illumina executive stock transactions Form 4 before material announcements.
- Navigate strategic announcements with Illumina 8-K material events explained.
- Review pay practices inside the latest Illumina proxy statement executive compensation section.
This hub answers popular investor questions like “Illumina SEC filings explained simply” and “understanding Illumina SEC documents with AI.” Real-time updates, concise red-flag summaries and downloadable spreadsheets mean you spend less time parsing accounting notes and more time deciding what Illumina’s breakthroughs mean for your portfolio.
Scott B. Ullem, a director of Illumina, Inc. (ILMN), reported on Form 4 that on 09/30/2025 he acquired 252 shares of Illumina common stock issued in lieu of cash retainer fees at an implied price of $99.1666 per share. Following the transaction he beneficially owns 8,389 shares, held directly. The filing states Mr. Ullem elected to receive 100% of his 2025 board and committee cash retainer fees in Illumina stock, with share counts determined using the quarter’s volume-weighted average closing price. The form is signed on 10/02/2025.
Illumina insider Steven Barnard, SVP and Chief Technology Officer, reported a sale of 287 shares of Common Stock on 09/05/2025 at a reported price of $98.93 per share, leaving him with 33,546 shares beneficially owned after the transaction. The Form 4 was signed by Robert Maynes on behalf of Mr. Barnard on 09/09/2025. The filing lists no derivative transactions.
Capital World Investors filed an amended Schedule 13G reporting beneficial ownership of 16,866,776 Illumina shares, representing 10.7% of the 158,300,000 shares believed to be outstanding. CWI reports sole voting power over 16,802,393 shares and sole dispositive power over 16,866,776 shares, and identifies itself as a division of Capital Research and Management Company. The filing states the securities were acquired and are held in the ordinary course of business and were not acquired to change or influence control of Illumina. The filing includes the issuer address, filer address, and CUSIP 452327109.
Illumina has entered into a significant Stock Purchase Agreement with Standard BioTools to acquire SomaLogic and Sengenics entities for $350 million in cash, plus potential milestone payments of up to $75 million. The deal, announced June 22, 2025, includes Standard BioTools' aptamer-based and functional proteomics business, featuring KREX and Single SOMAmer technologies.
Key transaction details:
- Purchase includes SomaLogic Inc, Sengenics Corporation LLC, and Sengenics Corporation Pte Ltd
- Deal includes transition services and license agreements
- Closing deadline set for March 23, 2026, with three possible 3-month extensions
- $14.5 million termination fee if deal fails due to regulatory clearance issues
The transaction is subject to customary closing conditions, including Hart-Scott-Rodino Act clearance and regulatory approvals. This strategic acquisition significantly expands Illumina's presence in the proteomics market, though the company notes several risk factors including integration challenges and market uncertainties.
FAQ
What is the current stock price of Illumina (ILMN)?
What is the market cap of Illumina (ILMN)?
